TEQ102 / Oncoteq, Gilead, Partex.AI - LARVOL DELTA

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy. (PubMed, Mol Cancer Ther) - "Taken together, TUB-010 is a novel, potential best-in-class anti-CD30 ADC with improved biophysical properties designed to deliver MMAE with higher precision and a wider therapeutic window than Adcetris using Tub-tag technology. Therefore, TUB-010 may increase the clinical benefit of anti-CD30 ADC therapies."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies (ASH 2022) - "Brentuximab-Vedotin (BV, Adcetris®), an MMAE-delivering anti-CD30-ADC, has a high response rate but dose-limiting AEs often result in premature dose reduction or even therapy discontinuation. Tub-tag technology allows the reduction of nonspecific target-independent toxicity of ADCs in preclinical models by improving key design issues in current ADCs such as stability and overall biophysical features. TUB-010 is a promising, novel and potential best-in-class CD30-ADC which can deliver the cytotoxic payload to CD30+ malignancies with higher precision and with a wider therapeutic window than BV. These features suggest that TUB-010 may increase the clinical benefit with CD30-targeting ADC therapy for patients with CD30+ malignancies."

Cutaneous T-cell Lymphoma • Hematological Disorders • Oncology • CTSB • TNFRSF8

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation (PRNewswire.co.uk) - "Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies...This approach has demonstrated superior stability and efficacy in preclinical studies...The first program from Tubulis' pipeline the companies will collaborate on is TUB-010...designed to treat patients with lymphoma...'We will leverage our advanced development platforms, large scientific teams dedicated to ADCs and industry-leading development timelines to bring TUB-010 towards the clinic.'"

Licensing / partnership • Hematological Malignancies • Lymphoma • Oncology